High-plex protein biomarker platforms market seen reaching $3.15 billion by 2030

By AI, Created 4:54 PM UTC, May 18, 2026, /AGP/ – The high-plex protein biomarker platforms market is projected to rise from $1.72 billion in 2025 to $3.15 billion by 2030, according to The Business Research Company. Growth is being driven by precision medicine adoption, broader translational research spending and expanding biomarker use in oncology and immunology.

Why it matters: - High-plex protein biomarker platforms are becoming a core tool for precision medicine because they can measure many protein biomarkers from a single sample. - The market’s growth points to more demand for faster diagnosis, better patient stratification and more tailored therapies.

What happened: - The Business Research Company released its High-Plex Protein Biomarker Platforms Market Report 2026, covering market size, trends and a global forecast through 2035. - The report projects the market will grow from $1.72 billion in 2025 to $1.94 billion in 2026. - The market is forecast to reach $3.15 billion by 2030, implying a 12.8% compound annual growth rate from 2026 to 2030. - The report was published May 15, 2026, in London. - The company offers a free sample of the report and the full market report.

The details: - High-plex protein biomarker platforms are advanced analytical tools that detect and quantify multiple protein biomarkers in one biological sample. - The platforms are designed to speed biomarker discovery and improve disease diagnosis, prognosis and patient stratification. - The report says recent growth reflects more investment in proteomics research, higher rates of chronic and complex disease, expanding pharmaceutical R&D, rising demand for early disease detection and mass spectrometry advances. - Future growth is linked to precision medicine, companion diagnostics development, translational research support, oncology and immunology biomarker studies, and next-generation proteomic platforms. - The report also cites ultra-high multiplex protein profiling, integrated multi-omics platforms, high-sensitivity immunoassays, and a push for better standardization and reproducibility in proteomics research. - North America was the dominant regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Precision medicine is the biggest commercial tailwind here because it depends on deeper biological profiling to match patients with treatments. - The market data suggests protein biomarker testing is moving from a research niche toward broader clinical and pharmaceutical use. - The regional split shows the sector is mature in North America but still has room for faster adoption in Asia-Pacific as healthcare spending and diagnostics capacity rise.

What’s next: - The market is expected to keep expanding through 2030 as personalized medicine and companion diagnostics gain wider use. - Additional growth will likely come from more translational research and higher use of advanced proteomic platforms in oncology and immunology. - The report positions standardization and reproducibility as key technical priorities for the next phase of market adoption.

The bottom line: - High-plex protein biomarker platforms are on track for steady double-digit growth as precision medicine turns advanced proteomics into a bigger part of drug development and disease care.